Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Invectys
- Target Recruit Count
- 6
- Registration Number
- NCT04515043
- Locations
- 🇫🇷
Saint Louis Hospital, Paris, France
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Invectys
- Target Recruit Count
- 26
- Registration Number
- NCT03265717
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
INVAC-1 Anti-Cancer hTERT DNA Immunotherapy
- Conditions
- Solid Tumors
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Invectys
- Target Recruit Count
- 26
- Registration Number
- NCT02301754
- Locations
- 🇫🇷
Hôpital Saint Louis, Paris, France
🇫🇷Hôpital Européen Georges Pompidou, Paris, France
News
ALLO-316 CAR-T Therapy Shows Promise in Renal Cell Carcinoma Trial, but Deaths Reported
• Allogene's ALLO-316 demonstrated a 38% overall response rate in renal cell carcinoma patients at dose level 2 in the TRAVERSE phase 1 trial. • In patients with high CD70 expression, ALLO-316 achieved a confirmed overall response rate of 33%, indicating potential for targeted therapy. • The trial reported a manageable safety profile, with mostly low-grade cytokine release syndrome, but included three on-study patient deaths. • ALLO-316, an off-the-shelf CAR-T therapy, shows potential as a novel treatment for metastatic RCC resistant to multiple therapeutic classes.